YorkBridge Wealth Partners LLC Cuts Stock Holdings in Amgen, Inc. (NASDAQ:AMGN)

YorkBridge Wealth Partners LLC trimmed its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 7.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,290 shares of the medical research company’s stock after selling 475 shares during the quarter. YorkBridge Wealth Partners LLC’s holdings in Amgen were worth $1,217,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AMGN. Carlton Hofferkamp & Jenks Wealth Management LLC increased its holdings in Amgen by 1.1% in the 3rd quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 4,694 shares of the medical research company’s stock worth $933,000 after acquiring an additional 50 shares in the last quarter. Carroll Financial Associates Inc. increased its holdings in Amgen by 0.8% in the 2nd quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after acquiring an additional 58 shares in the last quarter. Lincoln Capital Corp increased its holdings in Amgen by 0.3% in the 2nd quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after acquiring an additional 58 shares in the last quarter. Slow Capital Inc. increased its holdings in Amgen by 0.4% in the 2nd quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after acquiring an additional 58 shares in the last quarter. Finally, Nicholas Hoffman & Company LLC. increased its holdings in Amgen by 5.0% in the 2nd quarter. Nicholas Hoffman & Company LLC. now owns 1,207 shares of the medical research company’s stock worth $222,000 after acquiring an additional 58 shares in the last quarter. 76.33% of the stock is owned by hedge funds and other institutional investors.

Shares of Amgen stock traded down $1.68 during trading hours on Monday, reaching $201.04. 275,702 shares of the company’s stock were exchanged, compared to its average volume of 2,185,597. The business has a fifty day moving average of $199.46 and a two-hundred day moving average of $186.80. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. The company has a market capitalization of $122.08 billion, a P/E ratio of 13.96, a price-to-earnings-growth ratio of 2.69 and a beta of 1.11. Amgen, Inc. has a 1 year low of $166.30 and a 1 year high of $211.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating the consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The company’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.83 EPS. As a group, research analysts predict that Amgen, Inc. will post 14.33 EPS for the current year.

Several equities research analysts recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Monday, October 14th. They issued an “outperform” rating for the company. BMO Capital Markets set a $240.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Monday, September 30th. Cantor Fitzgerald set a $230.00 price target on shares of Amgen and gave the stock a “hold” rating in a report on Monday, September 30th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a report on Monday, September 30th. Finally, Cowen set a $231.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Sunday, September 29th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Amgen currently has an average rating of “Buy” and an average price target of $217.28.

In other news, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at approximately $2,990,141.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total transaction of $413,400.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at approximately $3,376,651.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,851 shares of company stock worth $3,671,900. Corporate insiders own 0.25% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Most Active Stocks

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.